The California Supreme Court on Thursday revived a class-action lawsuit that accuses Bayer of paying another drug company to delay introducing a generic version of a Bayer antibiotic.
The practice is known as “pay to delay” and can violate antitrust law, according to a 2013 US Supreme Court decision.
The unanimous ruling by the state’s highest court was aimed at a settlement reached by Bayer, the holder of a patent on Cipro, and Barr Laboratories Inc., which wanted to introduce a generic version of the popular antibiotic and challenged Bayer’s patent.
Under the settlement, Bayer agreed to pay Barr $398.1 million, and Barr agreed to postpone the marketing of its generic.
The settlement sparked several antitrust lawsuits, including nine class-action suits filed by California consumers.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI